3.2 Kinetics of IL-6, IL-10, and TGF-β in SFTS and COVID-19
patients.
We studied the kinetics of the IL-6, IL-10, and TGF-β levels in patients
with nonfatal SFTS and severe COVID-19 patients, and the results showed
that IL-10 is elevated earlier than IL-6 (Tables 1 and2 ).[7] In contrast, TGF-β is decreased
later (Tables 1 and 2 ).
Therefore, we studied the correlation between IL-6, IL-10, and TGF-β in
LPS-induced THP-1-derived macrophages treated with IL-6R and IL-10RA
polyclonal antibodies. The results showed that the level of IL-6 was
decreased and that of TGF-β increased when we treated with the IL-10RA
polyclonal antibody (Figure 3 and Supplemental table
5 ).
However, there were no significant differences between IL-6, IL-10, and
TGF-β in LPS-induced THP-1-derived macrophages treated with the IL-6R
polyclonal antibody (Figure 3 and Supplemental table
5 ).
We also treated THP-1-derived macrophages infected with SFTSV and
SARS-CoV-2 with the IL-10RA polyclonal antibody to determine the role of
IL-10 in SFTSV and SARS-CoV-2 infection and the results were similar to
those for LPS-induced THP-1-derived macrophages: the level of IL-6 was
decreased and that of TGF-β increased (Figures 4 and 5and Supplemental table 6 and 7 ).